Chapters

Transcript

Video

Why do you believe the results of LEADER, showing CV outcome reduction with liraglutide, are different from previous trials using GLP-1 RAs that failed to demonstrate CV risk reduction?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Luc Van Gaal, MD

Luc Van Gaal, MD

Professor of Medicine
Department of Endocrinology, Diabetology and Metabolism
Antwerp University Hospital
Antwerp, Belgium